2014.07.25. Innovimmune awarded NIH NIAID SBIR Phase II $3 Million grant for the development of its oral NCE INV-88 Macrophage Migration Inhibitory Factor (MIF) inhibitors for Autoimmune Diseases

Written By Adam Parks

Innovimmune is awarded a $3 million, three-year (2014-2017) National Institute of Health (NIH) Phase II SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAIAD) to advance the preclinical development of proprietary First-in-Class INV-88 Macrophage Migration Inhibitory Factor (MIF) inhibitors for Rheumatoid Arthritis, its novel proprietary oral small molecule MIF inhibitor portfolio in development for the treatment of autoimmune and rare diseases.

Adam Parks https://apollocreativeco.com
Previous

2014.11.05. Superior treatment efficacy of novel oral DMARDs: INV-17 ROR gamma & INV-88 MIF inhibitors in murine CIA to be presented at the 2014 ACR Annual Meeting in Boston
Next

2014.05.15. INV-17 ROR gamma inhibitor portfolio in preclinical development stage